跳转至内容
Merck
所有图片(1)

主要文件

Y0001318

Cefpodoxime proxetil for impurity H identification

European Pharmacopoeia (EP) Reference Standard

别名:

Cefpodoxime proxetil

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H27N5O9S2
CAS号:
分子量:
557.60
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

cefpodoxime

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

−20°C

InChI

1S/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h8-10,14,18H,6-7H2,1-5H3,(H2,22,23)(H,24,27)/b25-13-/t10?,14-,18-/m1/s1

InChI 密鑰

LTINZAODLRIQIX-FBXRGJNPSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Cefpodoxime proxetil for impurity H identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Md Salim Shakur et al.
Indian pediatrics, 44(11), 838-841 (2007-12-07)
In order to evaluate clinical and bacteriological efficacy of Cefpodoxime Proxetil (CP) in typhoid fever in comparison to cefixime (CF), we assessed 140 children with suspected typhoid fever. Fulfilling inclusion criteria finally 40 culture confirmed typhoid fever were allocated in
Vasu Kumar Kakumanu et al.
International journal of pharmaceutics, 317(2), 155-160 (2006-04-20)
Learning about the behavior of a drug in biological environment enables application of better formulation strategies to improve bioavailability of the same. Cefpodoxime proxetil (CP) is a prodrug, which is orally administered cephalosporin with only 50% absolute bioavailability. Despite previous
Momin A Mujeeb et al.
Indian journal of medical sciences, 65(2), 43-49 (2011-02-01)
Cefpodoxime is a semisynthetic third generation cephalosporin analogue with a relatively broader spectrum of antimicrobial activity against gram negative and gram positive organisms. This is attributed to their somewhat increased resistance to degradation by the betalactamase. Cefpodoxime shows good activity
Hakki Yilmaz et al.
Current drug safety, 8(2), 145-147 (2013-07-13)
We report a case of acute interstitial nephritis (AIN) and immune hemolytic anemia (IHA) associated with cefpodoxime therapy. A patient with a recent history of cefpodoxime proxetil treatment presented with elevated serum creatinine, oliguria, nausea, vomiting, and dyspnea. Evidence of
Santosh V Gandhi et al.
Hindustan antibiotics bulletin, 51(1-4), 24-28 (2009-01-01)
Two accurate, precise, sensitive and economical procedures for simultaneous estimation of Cefpodoxime proxetil and Potassium clavulanate in tablet dosage form have been developed. The methods employed were absorbance correction method (I) and first order derivative spectroscopic method (II). The first

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门